<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, a great therapeutic potential is being attributed to vascular endothelial growth factor (VEGF), which, on the contrary to NTs, does cross the BBB in sufficient concentrations [
 <xref rid="B20-ijms-19-01312" ref-type="bibr">20</xref>]. Besides its prominent role in angiogenesis, VEGF also exerts important protective effects on neurons. VEGF promotes the survival of cells overexpressing a mutated SOD1 G93A protein [
 <xref rid="B21-ijms-19-01312" ref-type="bibr">21</xref>,
 <xref rid="B22-ijms-19-01312" ref-type="bibr">22</xref>] and ameliorates the effects of glutamate excitotoxicity [
 <xref rid="B23-ijms-19-01312" ref-type="bibr">23</xref>]. In rodents, VEGF treatment leads to a delay of ALS onset, an improvement of motor functions, the protection of motoneurons and neuromuscular junctions, and increase in survival [
 <xref rid="B24-ijms-19-01312" ref-type="bibr">24</xref>,
 <xref rid="B25-ijms-19-01312" ref-type="bibr">25</xref>]. Overall, pre-clinical data on the VEGF role in ALS treatment is promising.
</p>
